RAIN News and Press, Rain Therapeutics Inc. From 02/23/23

NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that r...

NEWARK, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p...

Summary Shares have fallen by nearly 40% since 2021 IPO. Oral MDM2 inhibitor milademetan potentially has an efficient path to market via pivotal study in WD/DD LPS (rare cancer). Basket studies in MDM2-amplified tumors as well as patients with CDKN2A loss exponentially increase mark...

Summary Rain Oncology is a late-stage oncology company. Their lead product, milademetan, is an oral inhibitor of the MDM2-p53. In the past, MDM2 inhibitors have been associated with severe hematologic events. In an early study, milademetan showed a median PFS of 7.2 months in patients w...

NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Rain Oncology (NASDAQ: RAIN), the company is updating their presentation date and time to Thursday, February 9, 2023, at 3:55 p.m. ET. Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-sta...

Roth Capital has resumed coverage of Rain Oncology ( NASDAQ: RAIN ) with a buy rating saying that the company's lead candidate, milademetan for liposarcoma, has a positive risk/reward setup in advance of a Q1 data readout The firm has a price target of $21 (~117% upside based on Monda...

NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p...

– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in advanced dedifferentiated liposarcoma provides foundation for the ...

Biotechnology company Rain Therapeutics ( NASDAQ: RAIN ) is set to change its name to Rain Oncology, effective Dec. 30. The name change intends to better reflect the company's focus on addressing unmet needs for cancer patients through precision oncology. The company will also hav...

NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 com...